141 related articles for article (PubMed ID: 38520220)
21. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
22. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
[TBL] [Abstract][Full Text] [Related]
23. A transient receptor potential channel-related model based on machine learning for evaluating tumor microenvironment and immunotherapeutic strategies in acute myeloid leukemia.
Hua J; Ding T; Shao Y
Front Immunol; 2022; 13():1040661. PubMed ID: 36591215
[TBL] [Abstract][Full Text] [Related]
24. Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data.
You Y; Yang Q
BMC Cancer; 2024 Feb; 24(1):207. PubMed ID: 38355446
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
26. Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer.
Li N; Yu K; Huang D; Li S; Zeng D; Li J; Fan L
Biol Trace Elem Res; 2024 Apr; 202(4):1428-1445. PubMed ID: 37528285
[TBL] [Abstract][Full Text] [Related]
27. Integrative analysis of cuproptosis-associated genes for predicting immunotherapy response in single-cell and multi-cohort studies.
Li H; Wang Y; Li G; Xiong J; Qin L; Wen Q; Yue C
J Gene Med; 2024 Jan; 26(1):e3600. PubMed ID: 37776237
[TBL] [Abstract][Full Text] [Related]
28. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
[TBL] [Abstract][Full Text] [Related]
29. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unveils heterogeneity and establishes a novel signature for prognosis and tumor immune microenvironment in ovarian cancer.
Wang Z; Zhang J; Dai F; Li B; Cheng Y
J Ovarian Res; 2023 Jan; 16(1):12. PubMed ID: 36642706
[TBL] [Abstract][Full Text] [Related]
30. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
31. Glycosylation-Related Genes Predict the Prognosis and Immune Fraction of Ovarian Cancer Patients Based on Weighted Gene Coexpression Network Analysis (WGCNA) and Machine Learning.
Zhao C; Xiong K; Zhao F; Adam A; Li X
Oxid Med Cell Longev; 2022; 2022():3665617. PubMed ID: 35281472
[TBL] [Abstract][Full Text] [Related]
32. Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer.
Gao Y; Shi H; Zhao H; Yao M; He Y; Jiang M; Li J; Li Z; Su S; Liu T; Yin C; Liao X; Yue W
Clin Transl Med; 2023 Sep; 13(9):e1416. PubMed ID: 37712139
[TBL] [Abstract][Full Text] [Related]
33. Development and verification of a 7-lncRNA prognostic model based on tumor immunity for patients with ovarian cancer.
Feng J; Yu Y; Yin W; Qian S
J Ovarian Res; 2023 Feb; 16(1):31. PubMed ID: 36739404
[TBL] [Abstract][Full Text] [Related]
34. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
Cao T; Shen H
J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
[TBL] [Abstract][Full Text] [Related]
35. A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer.
Ding Q; Dong S; Wang R; Zhang K; Wang H; Zhou X; Wang J; Wong K; Long Y; Zhu S; Wang W; Ren H; Zeng Y
Aging (Albany NY); 2020 Mar; 12(6):4879-4895. PubMed ID: 32208363
[TBL] [Abstract][Full Text] [Related]
36. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
Zheng P; Li N; Zhan X
Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
[TBL] [Abstract][Full Text] [Related]
37. Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer.
Huan Q; Cheng S; Ma HF; Zhao M; Chen Y; Yuan X
J Cell Mol Med; 2024 Jan; 28(1):e18021. PubMed ID: 37994489
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
39. Identification of Stemness Characteristics Associated With the Immune Microenvironment and Prognosis in Gastric Cancer.
Mao D; Zhou Z; Song S; Li D; He Y; Wei Z; Zhang C
Front Oncol; 2021; 11():626961. PubMed ID: 33747944
[TBL] [Abstract][Full Text] [Related]
40. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
